Abpro Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABP research report →
About the company
Abpro Holdings, Inc. is a biotechnology firm dedicated to creating antibody-based treatments for patients suffering from conditions in immuno-oncology, ophthalmology, and autoimmunity. A key element of their strategy is the proprietary DiversImmune platform, which aims to resolve a significant hurdle in the antibody therapeutics sector.
- CEO
- Jin Wook Suk
- IPO
- 2022
- Employees
- 6
- HQ
- Woburn, MA, US
Price Chart
- Market Cap
- $1.06M
- P/E
- 0.24
- P/S
- 0.00
- P/B
- -339.87
- EV/EBITDA
- -1.81
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.36%
- ROIC
- 328.24%
- Revenue
- $183.00K · 50.00%
- Net Income
- $-7,232,000 · 38.22%
- EPS
- $-23.10 · 38.40%
- Op Income
- $-9,921,000
- FCF YoY
- -21.21%
- 52W High
- $18.03
- 52W Low
- $0.11
- 50D MA
- $2.72
- 200D MA
- $5.62
- Beta
- -0.00
- Avg Volume
- 1.72M
Get TickerSpark's AI analysis on ABP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ABP coverage
Recent articles, reports, and earnings notes.
No research on ABP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABP report →Similar companies
Peers in the same neighborhood.